Umeclidinium/vilanterol

Phase 3

GSK plc (GSK)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

2 competitors in Pulmonary Disease, Chronic Obstructive

View Full Landscape

Drug Information

Target Indication

Pulmonary Disease, Chronic Obstructive

Clinical Trial

NCT01817764

Last updated: 1/24/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA3/20/2017

Rolufta Ellipta (previously Rolufta)

Rolufta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

GSK

GSK plc

Pharmaceutical Preparations•Europe•NYSE

Related Pipeline

FluoridePhase 3

Dental Caries

Combined Hepatitis A and B vaccinePhase 3

Hepatitis B

62.5/25mcgPhase 3

Pulmonary Disease, Chronic Obstructive

Losmapimod 7.5 mg twice dailyPhase 3

Acute Coronary Syndrome

GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix)Phase 3

Infections, Meningococcal

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts